PRODUCTS

DISCOVER our current registered portfolio

Abiraterone acetate SPC ® is a type of hormonal therapy indicated for the treatment of:

newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with conventional hormonal therapy.

metastatic castration resistant prostate cancer (mCRPC) in combination with prednisone in adult men who are asymptomatic or mildly symptomatic after failure of conventional hormonal therapy in whom chemotherapy is not indicated.

mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Abiraterone acetate SPC ® is in the form of tablets with a concentration of 250 mg.

Abiraterone acetate SPC ® is orally administered with a convenient once daily dosing.

Abiraterone acetate SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Abiraterone acetate has been established by several international clinical trials.

Abiraterone acetate is approved for human use by different global health authorities like the United States Food and drug Administration and the European Medicine Agency as well as national regulatory bodies like Saudi Food and drug Authority.

Abiraterone acetate is also recognized as one of the most important treatments of prostate cancer by key guidelines like the US National Comprehensive Cancer Network.

If you miss a dose of Abiraterone SPC® or prednisone, take your prescribed dose the following day. If you miss more than 1 dose, tell your healthcare provider right away

Take Abiraterone SPC®  on an empty stomach, at least 1 hour before or at least 2 hours after a meal. Do not take Abiraterone SPC® with food. Taking Abiraterone SPC® with food may cause more of the medicine to be absorbed by the body than is needed and this may cause side effects

Abiraterone SPC®

Abiraterone acetate 250 mg film-coated tablets

Azacitidine SPC ® is an anti-cancer agent which belongs to a group of medicines called ‘anti-metabolites’.

Azacitidine SPC ® is used in adults who are not able to have a stem cell transplantation to treat:

higher-risk myelodysplastic syndromes (MDS).

chronic myelomonocytic leukaemia (CMML).

acute myeloid leukaemia (AML).

These are diseases which affect the bone marrow and can cause problems with normal blood cell production.

Azacitidine SPC ® prevents cancer cells from growing as it becomes incorporated into the genetic material of cells. It is thought to work by interfering with the production of new RNA and DNA. These actions are thought to correct problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders, and to kill cancerous cells in leukaemia.

Azacitidine SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Azacitidine has been established by several international clinical trials.

Azacitidine is approved for human use by different global health authorities like the USFDA and EMA as well as national regulatory bodies like Saudi FDA.

Azacitidine is also recognized as one of the most important treatments of MDS by key guidelines like the US National Comprehensive Cancer Network.

You usually have Azacitidine SPC® as an injection just under your skin (subcutaneously) given by a doctor or nurse. This can be in your upper arm, leg, buttock or stomach.

You might have stinging or a dull ache for a short time after this type of injection, but they don't usually hurt much. The skin in the area may go red and itchy for a while.

Azacitidine SPC ®

Abiraterone acetate 250 mg film-coated tablets

Bortezomib SPC ® falls under a drug class called ‘proteasome inhibitors’.

Bortezomib SPC ® (proteasomes) play an important role in controlling cell function and growth. By interfering with their function, bortezomib can kill cancer cells.

Bortezomib is used alone or in combination with other medicines like dexamethasone, lenalidomide, melphalan or others for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years.

Bortezomib is also used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone.

Bortezomib SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Bortezomib has been established by several international clinical trials.

Bortezomib is approved for human use by different global health authorities like the USFDA and the EMA as well as national regulatory bodies like Saudi FDA

Bortezomib is also recognized as one of the most important treatments of multiple myeloma by key guidelines like the US National Comprehensive Cancer Network.

Bortezomib SPC ®

Abiraterone acetate 250 mg film-coated tablets

Capecitabine SPC ® belongs to the group of medicines called "cytostatic medicines", which stop the growth of cancer cells. After being absorbed by the body is it changed into an active anti-cancer medicine (5-fluorouracil which is more accumulated in tumor tissue than in normal tissue).

Capecitabine SPC ® is used in the treatment of colon, rectal, gastric, or breast cancers.

Furthermore, Capecitabine SPC is used to prevent new occurrence of colon cancer after complete removal of the tumor by surgery.

Capecitabine SPC ® may be used either alone or in combination with other medicines.

Capecitabine SPC ® is in the form of tablets with a concentration of 150 or 500 mg.

Capecitabine SPC ® is orally administered with a convenient twice daily dosing.

Capecitabine SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Capecitabine has been established by several international clinical trials.

Capecitabine is approved for human use by different global health authorities like the United States Food and drug Administration and the European Medicine Agency as well as national regulatory bodies like Saudi Food and drug Authority.

Capecitabine is also recognized as one of the backbone treatments of colorectal cancer by key guidelines like the US National Comprehensive Cancer Network.

The amount of capecitabine that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.

Do not crush, chew or dissolve tablets.

Capecitabine SPC®

Abiraterone acetate 250 mg film-coated tablets

Docetaxel is a substance derived from the needles of yew trees.

Docetaxel SPC ® belongs to the group of anti‐ cancer medicines called taxanes.

Docetaxel SPC ® has been shown to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions during the cell replication process.

Docetaxel SPC ® is available in the form of vials with a concentration of 20 or 80 mg / vial given IV.

Docetaxel SPC ® is used for the treatment of breast cancer, special forms of lung cancer (non‐small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer.

Docetaxel SPC ® could be administered either alone or in combination with doxorubicin, trastuzumab, cisplatin, capecitabine, cyclophosphamide or others.

Docetaxel SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Docetaxel has been established by several international clinical trials.

Docetaxel is approved for human use by different global health authorities like the United States Food and Drug Administration and the European Medicine Agency as well as national regulatory bodies like Saudi Food and Drug Authority.

Docetaxel is also endorsed as one of essential treatments of several solid tumors like lung, breast, prostate and gastric cancers by key guidelines like the United States National Comprehensive Cancer Network.

Docetaxel SPC ®

Abiraterone acetate 250 mg film-coated tablets

Imatinib SPC ® is a medicine that works by inhibiting the growth of abnormal cells in the diseases listed below:

Philadelphia chromosome positive Chronic myeloid leukaemia (CML). Leukaemia is a cancer of white blood cells (named myeloid cells) start growing out of control.

Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL).
in which certain abnormal white cells (named lymphoblasts) start growing out of control

Myelodysplastic/myeloproliferative diseases (MDS/MPD).

Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL).

Dermatofibrosarcoma protuberans (DFSP). DFSP is a cancer of the tissue beneath the skin in which some cells start growing out of control.

Gastro-intestinal Stromal Tumor(GIST).

Imatinib SPC ® is in the form of tablets with a concentration of 100 or 400 mg.

Imatinib SPC ® is orally administered with a convenient once daily dosing.

Imatinib SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Imatinib has been established by several international clinical trials.

Imatinib is approved for human use by different global health authorities like the USFDA and the EMA as well as national regulatory bodies like SFDA.

Imatinib is also endorsed as one of essential treatments of several hematologic disorders by key guidelines like the European Leukemia Network.

Imatinib SPC ®

Abiraterone acetate 250 mg film-coated tablets

Lenalidomide SPC ® is a medicine that belongs to a group of medicines which affect how your immune system works called ‘immunomodulators’ (IMiDs).

Lenalidomide SPC works by stopping the cancer cells developing, by stopping blood vessels growing in the cancer and by stimulating part of the immune system to attack the cancer cells. Lenalidomide SPC could be given alone or in combination with other medicines.

Lenalidomide SPC ® is a treatment for:

Multiple myeloma(MM).

Myelodysplastic syndrome (MDS).

Mantle cell lymphoma (MCL).

Multiple myeloma is a type of cancer which affects a certain kind of white blood cells called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.

Lenalidomide SPC ® is orally administered with a convenient once daily dosing.

Lenalidomide SPC ® is a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Lenalidomide has been established by several international clinical trials.

Lenalidomide is approved for human use by different global health authorities like the USFDA and the EMA as well as national regulatory bodies like SFDA.

Lenalidomide is also recognized as one of essential treatments of several hematologic disorders by key guidelines like the NCCN.

Lenalidomide SPC®

Abiraterone acetate 250 mg film-coated tablets

Pemetrexed SPC ® is a medicine used in the treatment of certain types of cancer.

Pemetrexed is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.

Pemetrexed SPC ® is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.

Pemetrexed SPC ® is also given in combination with cisplatin for the initial treatment of patients with advanced stage lung cancer.

Pemetrexed SPC ® is available in the form of vials given Intravenously.

Pemetrexed SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Pemetrexed has been established by several international clinical trials.

Pemetrexed is approved for human use by different global health authorities like the United States Food and Drug Administration and the European Medicine Agency as well as national regulatory bodies like Saudi Food and Drug Authority.

Pemetrexed is also recognized as one of essential treatments of Lung Cancer by key guidelines like the United States National Comprehensive Cancer Network.

Patients treated with pemetrexed will usually require folic acid and vitamin B12 supplementation to reduce treatment related side effects.

Pemetrexed SPC ®

Abiraterone acetate 250 mg film-coated tablets

Zoledronic Acid SPC ® 5mg belongs to a group of medicines called bisphosphonates.

Zoledronic Acid SPC ® 5mg is mainly used to treat Osteoporosis.

Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men.

Osteoporosis could also occur in men and women because of the long-term use of steroids.

In both women and men, Zoledronic Acid SPC strengthens the bone and therefore makes it less likely to break.

It is normal that old bone is removed and is replaced with new bone material. This process is called remodeling. Bone remodeling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal.

Zoledronic Acid SPC ® 5mg works by returning the bone remodeling process to normal, securing formation of normal bone, thus restoring strength to the bone.

Zoledronic Acid SPC ® is administered with a convenient once yearly dosing intravenously.

The safety and efficacy of Zoledronic Acid has been established by several international clinical trials.

Zoledronic Acid is approved for human use by different global health authorities like the USFDA and the EMA as well as national regulatory bodies like SFDA.

On the day of the infusion, it is important to drink at least 500 mL (2 cups) of fluids before and after the treatment.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications.

It is recommended that people taking this medication take calcium and vitamin D supplements to prevent low blood calcium levels. Your doctor will recommend a dose of these supplements based on your needs.

Zoledronic Acid SPC ® 5mg/100 ml

Abiraterone acetate 250 mg film-coated tablets

Fingolimod SPC ® is a medicine belongs to a group of medicine called “Sphingosine 1-phosphate receptor modulators”. The mechanism of action of fingolimod is incompletely understood but appears to be fundamentally different from other MS medications. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. Fingolimod promotes sequestration of lymphocytes within the lymph nodes, which may reduce lymphocyte migration into the central nervous system.

Fingolimod SPC ® is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient groups:

Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).

Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

Fingolimod SPC ® is in the form of tablets with a concentration of 0.5mg.

Fingolimod SPC ® is orally administered with a convenient once daily dosing.

Fingolimod SPC ® a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Fingolimod has been established by several international clinical trials.

Fingolimod SPC ® is approved by SFDA to be used for the pervious indication under registration number: 0810200201.

Fingolimod SPC®

Abiraterone acetate 250 mg film-coated tablets

Pomalidomide SPC ® is a medicine that belongs to a group of medicines which affect how your immune system works, an analogue of thalidomide, is an immunomodulatory antineoplastic agent.

Pomalidomide SPC works by Inhibiting the proliferation and induce apoptosis of hematopoietic tumor cells, Inhibiting the proliferation of lenalidomide-resistant multiple myeloma cell lines and have immunomodulatory activity. Pomalidomide enhanced T cell- and natural killer cell-mediated immunity

Pomalidomide SPC ® could be given alone or in combination with other medicines.

Pomalidomide SPC ® is used for:

  • in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
  • in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Multiple myeloma is a type of cancer which affects a certain kind of white blood cells called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.

Pomalidomide SPC ® is orally administered with a convenient once daily dosing.

Pomalidomide SPC ® is a prescription medication that should be given only by an authorized healthcare professional.

The safety and efficacy of Pomalidomide has been established by several international clinical trials.

Pomalidomide is approved for human use by different global health authorities like the USFDA and the EMA as well as national regulatory bodies like SFDA.

Pomalidomide SPC®

Abiraterone acetate 250 mg film-coated tablets

Carfilzomib SPC ® is a targeted therapy, classified as a Proteasome Inhibitor.

Carfilzomib SPC ® is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Carfilzomib SPC ® could be given alone or in combination with other medicines.

Carfilzomib SPC ® is used for:

  • Carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • Carfilzomib is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • Multiple myeloma is a type of cancer which affects a certain kind of white blood cells called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.

Carfilzomib SPC ®  administered intravenously over 2 to 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.

Carfilzomib SPC ® is a prescription medication that should be given only by an authorized healthcare professional.

Carfilzomib SPC®

Abiraterone acetate 250 mg film-coated tablets

Sudair Pharmaceutical Company

Copyright © 2021 Sudair Pharma - All Rights Reserved.